【摘要】：目的：觀察樹突狀細(xì)胞（DC）聯(lián)合細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞（CIK）免疫治療對(duì)腎癌術(shù)后患者免疫功能的影響。 方法：回顧性分析2011年9月至2013年6月期間在我院確診的52例腎癌患者，均采取腎癌根治性切除手術(shù)或保留腎單位手術(shù)，術(shù)后隨訪過程中曾予以行DC聯(lián)合CIK細(xì)胞輔助免疫治療，分別于治療前一周、治療后兩周，抽取患者外周血采用流式細(xì)胞術(shù)和酶聯(lián)免疫吸附法檢測(cè)患者免疫功能指標(biāo)，包括外周血CD3+、CD4+、CD8+T淋巴細(xì)胞亞群百分比、CD4+/CD8+的比值，以及外周血INF-、IL-2、IL-10等細(xì)胞因子水平；同時(shí)記錄回輸過程中的毒副反應(yīng)，以及評(píng)估患者的生活質(zhì)量。 結(jié)果：1.治療后兩周外周血CD3+、CD4+T淋巴細(xì)胞百分比、CD4+/CD8+的比值、IL-2、INF-水平較治療前一周升高，2.治療后兩周外周血CD8+T淋巴細(xì)胞百分比、IL-10水平較治療前一周下降，前后兩者比較差異均有統(tǒng)計(jì)學(xué)意義(淋巴細(xì)胞比例P0.05，細(xì)胞因子P0.01)；3.治療過程中，毒副反應(yīng)較少，患者的生活質(zhì)量較前明顯改善。 結(jié)論：DC聯(lián)合CIK細(xì)胞免疫治療能顯著改善腎癌術(shù)后患者的免疫失衡狀態(tài)，激發(fā)特異性免疫應(yīng)答，提高患者的免疫功能；患者不良反應(yīng)較少，耐受性良好；可能降低腎癌術(shù)后腫瘤的復(fù)發(fā)率，并且對(duì)于轉(zhuǎn)移性腎癌的治療也顯現(xiàn)一定的療效。
[Abstract]:Aim: to observe the effect of dendritic cell (DC) combined with cytokine induced killer cell (CIK) immunotherapy on immune function of patients with renal cell carcinoma after operation. Methods: from September 2011 to June 2013, 52 patients with renal cell carcinoma diagnosed in our hospital were treated with radical resection of renal cell carcinoma or nephron-sparing surgery. DC combined with CIK cell adjuvant immunotherapy was performed during follow-up. Flow cytometry and enzyme-linked immunosorbent assay (Elisa) were used to detect the immune function, including the percentage of CD3, CD4, CD8 T lymphocyte subsets and the ratio of CD4 / CD8. And the level of cytokines such as INF-,IL-2,IL-10 in peripheral blood; Side effects were also recorded during retransfusion and quality of life was assessed. Results: 1. Two weeks after treatment, the percentage of CD3, CD4 T lymphocytes, the ratio of CD4 / CD8, and the level of IL-2,INF- in peripheral blood were higher than those in the week before treatment. Two weeks after treatment, the percentage of CD8 T lymphocytes and the level of IL-10 in peripheral blood were significantly lower than those before treatment (P 0.05, cytokine P0.01). In the course of treatment, the side effects were less and the quality of life was improved obviously. Conclusion: DC combined with CIK cell immunotherapy can significantly improve the immune imbalance, stimulate specific immune response and improve the immune function of patients with renal cell carcinoma, with less adverse reactions and good tolerance. It may reduce the recurrence rate of renal cell carcinoma after operation, and also show certain curative effect for metastatic renal cell carcinoma.
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.11

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳復(fù)興,劉軍權(quán),張南征,鞏新建,張國龍,徐永茂,周忠海,王濤,黃健;自身細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞過繼性免疫治療惡性腫瘤的臨床觀察[J];癌癥;2002年07期

2 李雪梅,孫抒,王建光,李香丹,楊萬山;γ-干擾素對(duì)MGC-803胃癌細(xì)胞株誘導(dǎo)凋亡作用及其機(jī)制研究[J];臨床醫(yī)學(xué);2005年01期

3 宋傳科;陳立軍;黃晨;趙立;曲楠;王亞林;麥海星;;樹突狀細(xì)胞和細(xì)胞因子誘導(dǎo)殺傷細(xì)胞聯(lián)合白介素2治療腎癌臨床觀察[J];軍事醫(yī)學(xué);2012年01期

4 李建旺;黃春珍;李建華;彭大為;;自體CIK細(xì)胞及DC細(xì)胞聯(lián)合索拉非尼治療轉(zhuǎn)移性腎癌的療效與安全性[J];山東醫(yī)藥;2012年01期

5 張有順,黃玲,楊紅玲,郝金波,王波,戴宗晴;肝癌患者CIK細(xì)胞的誘導(dǎo)及對(duì)肝癌細(xì)胞毒作用的研究[J];上海免疫學(xué)雜志;2003年03期

6 徐永茂;徐冬云;張南征;陳復(fù)興;劉軍權(quán);;化療聯(lián)合過繼免疫細(xì)胞治療晚期非小細(xì)胞肺癌的臨床研究[J];實(shí)用癌癥雜志;2010年02期

7 管德輝;王曉民;蘇宇;王科亮;徐萬海;;腎細(xì)胞癌患者手術(shù)前后外周血T淋巴細(xì)胞亞群的變化及其臨床意義[J];武警醫(yī)學(xué);2012年03期

8 張輝;趙群;左連富;馬洪俊;李淑榮;程建新;賈金華;康山;;細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞對(duì)卵巢癌耐藥細(xì)胞SKOV3/CDDP的作用機(jī)制[J];細(xì)胞與分子免疫學(xué)雜志;2007年12期

9 莊捷;曹暉;劉祥麟;張尚權(quán);;樹突狀細(xì)胞與CIK細(xì)胞共培養(yǎng)誘生的DCCIK細(xì)胞群對(duì)腫瘤的殺傷作用[J];細(xì)胞生物學(xué)雜志;2007年02期

10 李曉英;鮑楊漪;江蓓蕾;李玉芝;方紅嬌;;不同類型腫瘤患者自體CIK細(xì)胞治療對(duì)機(jī)體免疫狀態(tài)及臨床癥狀改善的影響[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2012年04期

，

本文編號(hào)：2390952